Etanercept treatment for autoimmune inner ear disease: Results of a pilot placebo-controlled study

Otology and Neurotology

Volumn 26, Issue 5, 2005, Pages 903-907

  Cohen, Stanley ^a,e   Shoup, Angela ^b   Weisman, Michael H ^c   Harris, Jeffrey ^d  

^a St Paul University Medical Center   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

Autoimmune inner ear disease; Etanercept

Indexed keywords

CORTICOSTEROID; ETANERCEPT; PREDNISONE;

ADULT; ARTICLE; AUDITORY THRESHOLD; AUTOIMMUNE DISEASE; AUTOIMMUNE INNER EAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FEMALE; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; IDIOPATHIC DISEASE; IMMUNOMODULATION; INNER EAR DISEASE; MALE; PILOT STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SIDE EFFECT; SPEECH DISCRIMINATION; VERTIGO;

AUDITORY THRESHOLD; AUTOIMMUNE DISEASES; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LABYRINTH DISEASES; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 24944479993     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/01.mao.0000185082.28598.87     Document Type: Article

References (14)

1. Harris JP, Sharp P. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;97:63-76.
2. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585-9.
3. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-52.
4. Maltesen EL, Tirzaman O, Facer GW, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-4.
5. Harris JP, Weisman MH, Derebery JM, et al. Treatment of corticosteroid- responsive autoimmune inner ear disease with methotrexate. JAMA 2003;290:1875-83.
6. Saracaydin A, Katircioglu S, et al. Azathioprine in combination with steroids in the treatment of autoimmune inner ear disease. J Int Med Res 1993;21:192-6.
7. Luete C. Theoretical and practical implications for plasmapheresis in autoimmune inner ear disease. Laryngoscope 1989;99:1137-46.
8. Broughton S, Cohen S, Meyerhoff W. Immune mediated inner ear disease. Semin Arthritis Rheumat 2004;34:544-8.
9. Wang X, Troung T, Billings P, Harris J, Keithley E. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurol 2000;24:52-7.
10. Rahman M, Poe D, Choi H. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurol 2001;22:619-24.
11. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope 1999;109:1749-54.
12. Gottslich S, Billings P, Keithley E, et al. Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Ménière's disease. Laryngoscope 1995;104:1347-52.
13. Owens E, Raggio M. Performance inventory for profound and severe hearing loss. J Speech Hearing Disorders 1988;53:42-56.
14. Choi H, Poe D, Wise C, et al. Etanercept therapy for immune mediated cochleovestibular disorders: an open-label, pilot trial. Arthritis Rheumat 2004;50:S235.